The European Centre of Excellence for preclinical cardiovascular electrophysiology.
The ApconiX team is pleased to announce their alliance with PhysioStim to create a new Centre of Excellence dedicated to cardiac safety studies. Both companies team up to offer a complete range of services in nonclinical cardiovascular electrophysiology.
ApconiX, based at Alderley Park in the U.K. and PhysioStim, based in Lautrec, France, are excited to announce their recent alliance to create a European Centre of Excellence for nonclinical cardiac electrophysiology. Both companies combine their extensive expertise to offer a complete range of preclinical cardiac safety studies, including automated electrophysiology providing hERG screening and CiPA ion channel assays, GLP compliant assays: manual patch-clamp assays (hERG, hNav1.5, hCav1.2), action potential recordings, Langendorff models and cardiac contractility studies.
The new Centre of Excellence is especially good news for pharmaceutical and biotech R&D companies that develop new drugs and compounds. These companies often struggle to determine the right lead candidates early in the drug development process. In the preclinical study phase, inefficient screening of potential lead candidates leads to soaring R&D costs for drug projects that will ultimately need to be abandoned due to toxicity issues.
The ApconiX and PhysioStim alliance is designed to help companies make better decisions when it comes to selecting the optimal clinical lead candidate at an early stage. The new Centre of Excellence will provide a complete set of preclinical cardiac safety studies, from screening to customized problem-solving studies, both in the GLP and non-GLP format. Customers will also benefit from a single contact person within the Centre of Excellence to directly access the companies’ expert electrophysiologists and toxicologists, who will help them interpret study and assay data and define the implications for each drug project.
“We are delighted to announce our alliance with ApconiX. This will give our clients unique access to a full range of high-quality services, from standard study models to more complex human cardiomyocyte-derived hiPSC models. They will benefit from our complementary expertise and the latest techniques to obtain the most effective results on platforms that are entirely dedicated to cardiac safety”
Marie Le Grand CEO of PhysioStim
“At ApconiX, we’re very excited about our new alliance with PhysioStim. Clients will benefit from a single point of contact to access a broad range of assays and extensive expertise in cardiac safety. Marie and her team bring significant experience and GLP-compliance to our comprehensive know-how in ion channel screening and drug development.”
Michael Morton Director and co-Founder of ApconiX
About ApconiX & PhysioStim
ApconiX provides expert nonclinical safety strategies and ion channel screening procedures to maximize the value of pharmaceutical assets at all stages of drug discovery and development. From target review to regulatory approval, ApconiX helps organizations to assess, reduce and manage potential risk factors in order to make better decisions in selecting the right drug candidate. The company’s experts design and deliver the optimal non-clinical strategy to quickly implement clinical programs in order to obtain marketing approval. ApconiX helps organisations bring safe, effective and profitable drugs to the market.
PhysioStim specializes in advanced study models to evaluate cardiac safety. The company is recognized as one of Europe’s most reliable CROs and has never ceased to improve its expertise in cardiac safety pharmacology. PhysioStim’s expertise covers electrophysiological studies, preclinical resources and a profound working knowledge of ICH S7B guidelines in accordance with GLP.
Dr Michael Morton PhD. A co-founder of ApconiX, Mike is an expert electrophysiologist and ion channel biologist with extensive experience gained in academia and industry. Mike’s career has spanned pure research, ion channel assay development and large-scale screening of all manner of ligand- and voltage-gated ion channels. Mike learned his craft as a postdoctoral fellow first at Leeds (with Malcolm Hunter) then at Yale (with Fred Sigworth) before joining the global ion channel initiative at AstraZeneca where his skills were applied to drug projects. Mike has a serious passion for ion channels and enjoys working with collaborators and clients alike to ensure the highest quality data are used to support better decision-making.